Irinotecan Dosing: Does the CPT in CPT-11 Stand for “Can’t Predict Toxicity”?
- 1 January 2002
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (1) , 7-8
- https://doi.org/10.1200/jco.2002.20.1.7
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liverJournal of Pharmaceutical Sciences, 2001
- Body Surface Area as a Determinant of Pharmacokinetics and Drug DosingInvestigational New Drugs, 2001
- Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical ImplicationsAnnals of the New York Academy of Sciences, 2000
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissuesBritish Journal of Cancer, 1999
- Recommended guidelines for the treatment of chemotherapy-induced diarrhea.Journal of Clinical Oncology, 1998
- UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecanAnnals of Oncology, 1998
- Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.Journal of Clinical Investigation, 1998
- Characterisation and Clinical Management of CPT-11 (Irinotecan)-induced Adverse Events: The European PerspectiveEuropean Journal Of Cancer, 1996
- Phase I and pharmacokinetic trial of weekly CPT-11.Journal of Clinical Oncology, 1993